Oramed Pharmaceuticals (NASDAQ:ORMP) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Oramed Pharmaceuticals (NASDAQ:ORMP) issued its quarterly earnings data on Thursday. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.04, Zacks reports.

Oramed Pharmaceuticals Stock Performance

Oramed Pharmaceuticals stock opened at $2.21 on Friday. Oramed Pharmaceuticals has a fifty-two week low of $1.96 and a fifty-two week high of $3.09. The stock has a market cap of $89.09 million, a P/E ratio of 20.09 and a beta of 1.61. The firm’s fifty day moving average price is $2.30 and its 200-day moving average price is $2.35.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, February 19th.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.